Bio-Techne Corporation’s Stock Price Drops by 6.85% to $67.57: A Detailed Analysis

Bio-Techne Corporation (TECH)

67.57 USD -4.97 (-6.85%) Volume: 2.45M

Bio-Techne Corporation’s stock price is currently at 67.57 USD, reflecting a significant dip of -6.85% in this trading session with a trading volume of 2.45M shares. The stock has been underperforming with a YTD percentage change of -11.34%, highlighting the need for potential investors to monitor this biotechnology firm closely.

Latest developments on Bio-Techne Corporation

Bio-Techne Corp is set to showcase innovative solutions for cancer and carrier screening at the upcoming AMP 2024 Annual Meeting & Expo, driving anticipation among investors. This comes as Royce & Associates LP acquires 17,296 shares of Bio-Techne Co. (NASDAQ: TECH), indicating growing interest in the company’s potential. Additionally, Geneva Capital Management LLC reveals a substantial $88.27 million holdings in Bio-Techne Co. (NASDAQ: TECH), further boosting confidence in the company’s future prospects and potentially influencing stock price movements today.

Bio-Techne Corporation on Smartkarma

Analysts at Baptista Research on Smartkarma have been closely monitoring Bio Techne Corp, a leading life sciences company. In their recent research reports, they highlighted the company’s solid performance in the first quarter of Fiscal Year 2025, with a 4% year-over-year organic revenue growth. This growth was attributed to the stabilization of biopharma end markets and robust execution in areas such as cell and gene therapy. Baptista Research aims to evaluate various factors that could impact the company’s stock price in the near future and is conducting an independent valuation using a Discounted Cash Flow (DCF) methodology.

Furthermore, Baptista Research also analyzed Bio Techne Corp‘s enhanced investment in molecular diagnostics during the company’s earnings call for the fourth quarter of fiscal year 2024. Despite a complex external environment with reduced biotech funding and budget recalibrations from large pharmaceutical entities and academia, Bio Techne Corp achieved modest organic revenue growth of 1% year-over-year. The analysts at Baptista Research continue to assess the company’s performance and potential, providing valuable insights for investors on Smartkarma.

A look at Bio-Techne Corporation Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, Bio Techne Corp has a promising long-term outlook. With a high Momentum score of 4, the company is showing strong growth potential and market performance. Additionally, Bio Techne Corp scores well in the Value and Growth categories, indicating a solid foundation for future success. However, the company’s lower scores in Dividend and Resilience suggest some areas for improvement to ensure stability and shareholder returns.

Overall, Bio Techne Corp is a biotechnology company that focuses on developing, manufacturing, and selling a range of products in the healthcare industry. Specializing in proteins, cytokines, growth factors, immunoassays, and small molecules, the company has established itself as a key player in the biotech sector. With a mix of positive and areas for growth based on the Smartkarma Smart Scores, Bio Techne Corp is poised for continued success in the evolving healthcare market.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma